Security key
52886X107
Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO)
CUSIP: 52886X107
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Shares outstanding
- 74,507,639
- Total 13F shares
- 76,464,347
- Share change
- +26,742,063
- Total reported value
- $759,231,269
- Put/Call ratio
- 99%
- Price per share
- $9.93
- Number of holders
- 145
- Value change
- +$269,440,349
- Number of buys
- 104
- Number of sells
- 35
Report period
Q4 2025
Institutions
145
Top holders
10
LXEO full security history
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Lexeo Therapeutics, Inc. SEC filings
Lexeo Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 52886X107
Recent filing periods:
Top shareholders of LXEO - Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC |
13D/G
13F
|
Company |
10%
|
7,291,434
|
$65,914,563 | +$10,720,599 | 28 Nov 2025 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
6.7%
|
4,885,814
|
$48,518,087 | +$26,984,571 | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13D/G
13F
|
Kenneth Griffin · Company |
7.4%
|
5,498,219
|
$40,851,767 | +$1,219,315 | 31 Dec 2025 | |
| Longitude Capital Partners IV, LLC |
3/4/5
13D/G
|
10%+ Owner |
3.8%
from 13D/G
|
2,567,100
|
$33,933,468 | — | 07 Nov 2023 | |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
— |
6.9%
|
5,000,000
|
$33,200,000 | $0 | 20 Oct 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
5.9%
|
4,424,725
|
$29,380,174 | — | 30 Sep 2025 | |
| Omega Fund VI, L.P. |
3/4/5
13D/G
|
10%+ Owner |
3.6%
from 13D/G
|
2,157,623
|
$28,520,755 | — | 07 Nov 2023 | |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
— |
5.1%
|
3,698,271
|
$27,478,154 | +$4,642,294 | 31 Dec 2025 | |
| Vestal Point Capital, LP |
13D/G
13F
|
Company |
7.5%
|
4,117,302
|
$27,338,885 | +$5,903,896 | 30 Sep 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
5.3%
|
3,913,788
|
$25,987,552 | — | 30 Sep 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
5.2%
|
3,870,527
|
$25,700,299 | — | 30 Sep 2025 | |
| Invest A/s Lundbeckfond |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,835,959
|
$24,268,808 | — | 07 Nov 2023 | |
| Woodline Partners LP |
13F
|
Company |
3.5%
|
2,572,162
|
$17,079,156 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
3.1%
|
2,313,642
|
$15,362,583 | — | 30 Sep 2025 | |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
|
Millennium Management LLC |
3.2%
|
2,313,642
|
$15,362,583 | -$3,470,396 | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3%
|
2,226,290
|
$14,782,566 | — | 30 Sep 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
2.6%
|
1,941,849
|
$12,893,875 | — | 30 Sep 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
2.1%
|
1,531,953
|
$10,172,168 | — | 30 Sep 2025 | |
| MIZUHO FINANCIAL GROUP INC |
13D/G
|
— |
6.6%
|
2,203,631
|
$8,109,362 | +$1,020,464 | 31 Mar 2025 | |
| Blackstone Inc. |
13F
|
Company |
1.5%
|
1,124,922
|
$7,469,482 | — | 30 Sep 2025 | |
| D1 Capital Partners L.P. |
13F
13D/G
|
Company |
2.9%
from 13D/G
|
978,652
|
$6,498,249 | — | 30 Sep 2025 | |
| 683 Capital Management, LLC |
13F
|
Company |
1.2%
|
922,662
|
$6,126,476 | — | 30 Sep 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.2%
|
912,533
|
$6,059,280 | — | 30 Sep 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1%
|
778,611
|
$5,169,977 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.97%
|
721,881
|
$4,794,441 | — | 30 Sep 2025 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13D/G
|
— |
3.7%
|
1,234,834
|
$4,544,189 | $0 | 31 Dec 2024 | |
| Siren, L.L.C. |
13F
|
Individual |
0.81%
|
603,435
|
$4,006,808 | — | 30 Sep 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.76%
|
567,601
|
$3,768,870 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.73%
|
544,845
|
$3,617,771 | — | 30 Sep 2025 | |
| Verition Fund Management LLC |
13F
|
Company |
0.56%
|
414,863
|
$2,754,690 | — | 30 Sep 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.48%
|
358,083
|
$2,377,671 | — | 30 Sep 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.47%
|
347,923
|
$2,310,208 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.34%
|
249,909
|
$1,659,395 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.32%
|
236,453
|
$1,570,047 | — | 30 Sep 2025 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.26%
|
192,356
|
$1,277,244 | — | 30 Sep 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.24%
|
180,744
|
$1,200,140 | — | 30 Sep 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.22%
|
166,538
|
$1,105,812 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.2%
|
149,300
|
$991,352 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.19%
|
142,402
|
$945,549 | — | 30 Sep 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.19%
|
139,835
|
$928,504 | — | 30 Sep 2025 | |
| Adage Capital Management, L.P. |
13D/G
|
— |
0.7%
|
237,953
|
$875,667 | -$7,255,716 | 31 Mar 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.17%
|
129,472
|
$859,694 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.15%
|
111,579
|
$740,885 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.14%
|
105,760
|
$702,246 | — | 30 Sep 2025 | |
| Eric Adler |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
160,146
mixed-class rows
|
$673,428 | -$38,781 | 18 Nov 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.13%
|
98,057
|
$651,097 | — | 30 Sep 2025 | |
| Jenny Robertson |
3/4/5
|
Chief Legal Officer |
—
mixed-class rows
|
140,881
mixed-class rows
|
$633,891 | -$39,149 | 18 Nov 2025 | |
| Tai Sandi See |
3/4/5
|
Chief Development Officer |
—
mixed-class rows
|
142,976
mixed-class rows
|
$606,962 | -$40,128 | 18 Nov 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.11%
|
84,763
|
$562,826 | — | 30 Sep 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.1%
|
71,677
|
$475,936 | — | 30 Sep 2025 |
Institutional Holders of Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO) as of Q4 2025
As of 31 Dec 2025,
Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO) was held by
145 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
76,464,347 shares.
The largest 10 holders included
JANUS HENDERSON GROUP PLC, RA CAPITAL MANAGEMENT, L.P., BlackRock, Inc., Paradigm Biocapital Advisors LP, Vestal Point Capital, LP, Frazier Life Sciences Management, L.P., VANGUARD GROUP INC, CITADEL ADVISORS LLC, Avoro Capital Advisors LLC, and Affinity Asset Advisors, LLC.
This page lists
145
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
108
Q4 2025 holders
145
Holder diff
37
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.